De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
ERF Overzicht aandelen
Eurofins Scientific SE biedt samen met haar dochterondernemingen wereldwijd verschillende analytische test- en laboratoriumdiensten aan.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 4/6 |
| Toekomstige groei | 3/6 |
| Prestaties in het verleden | 1/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 0/6 |
Eurofins Scientific SE Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | €56.78 |
| 52 Week Hoogtepunt | €62.10 |
| 52 Week Laag | €39.47 |
| Bèta | 0.68 |
| 11 maand verandering | 9.95% |
| 3 maanden verandering | 27.48% |
| 1 Jaar Verandering | 9.19% |
| 33 jaar verandering | -46.52% |
| 5 jaar verandering | 27.60% |
| Verandering sinds IPO | 23,760.15% |
Recent nieuws en updates
Earnings Tell The Story For Eurofins Scientific SE (EPA:ERF)
Aug 17
Results: Eurofins Scientific SE Beat Earnings Expectations And Analysts Now Have New Forecasts
Jul 27Recent updates
Earnings Tell The Story For Eurofins Scientific SE (EPA:ERF)
Aug 17Results: Eurofins Scientific SE Beat Earnings Expectations And Analysts Now Have New Forecasts
Jul 27These 4 Measures Indicate That Eurofins Scientific (EPA:ERF) Is Using Debt Extensively
May 10We Discuss Why Eurofins Scientific SE's (EPA:ERF) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year
Apr 19Eurofins Scientific SE's (EPA:ERF) Price In Tune With Earnings
Apr 18Does Eurofins Scientific (EPA:ERF) Have A Healthy Balance Sheet?
Nov 10Eurofins Scientific SE's (EPA:ERF) Intrinsic Value Is Potentially 64% Above Its Share Price
Oct 23We Think Eurofins Scientific (EPA:ERF) Is Taking Some Risk With Its Debt
Aug 07Are Investors Undervaluing Eurofins Scientific SE (EPA:ERF) By 25%?
Jul 20We Think Eurofins Scientific (EPA:ERF) Can Stay On Top Of Its Debt
May 03Eurofins Scientific SE (EPA:ERF) Shares Could Be 21% Above Their Intrinsic Value Estimate
Apr 11Estimating The Intrinsic Value Of Eurofins Scientific SE (EPA:ERF)
Jan 05Here's Why Eurofins Scientific (EPA:ERF) Can Manage Its Debt Responsibly
Dec 14An Intrinsic Calculation For Eurofins Scientific SE (EPA:ERF) Suggests It's 33% Undervalued
Oct 03Does Eurofins Scientific (EPA:ERF) Have A Healthy Balance Sheet?
Sep 06Eurofins Scientific (EPA:ERF) Is Increasing Its Dividend To €1.00
Jun 25Are Investors Undervaluing Eurofins Scientific SE (EPA:ERF) By 39%?
Jun 16Eurofins Scientific (EPA:ERF) Has A Rock Solid Balance Sheet
Jun 01Should You Be Adding Eurofins Scientific (EPA:ERF) To Your Watchlist Today?
Apr 12These 4 Measures Indicate That Eurofins Scientific (EPA:ERF) Is Using Debt Safely
Feb 25Is Eurofins Scientific SE (EPA:ERF) Worth €114 Based On Its Intrinsic Value?
Nov 28Eurofins Scientific (EPA:ERF) Has A Rock Solid Balance Sheet
Nov 14Here's Why I Think Eurofins Scientific (EPA:ERF) Might Deserve Your Attention Today
Sep 30Are Eurofins Scientific SE (EPA:ERF) Investors Paying Above The Intrinsic Value?
Aug 29We Think Eurofins Scientific (EPA:ERF) Can Manage Its Debt With Ease
Aug 15Do Eurofins Scientific's (EPA:ERF) Earnings Warrant Your Attention?
Jun 24Estimating The Fair Value Of Eurofins Scientific SE (EPA:ERF)
May 25Eurofins Scientific (EPA:ERF) Has A Rock Solid Balance Sheet
Mar 31Does Eurofins Scientific (EPA:ERF) Deserve A Spot On Your Watchlist?
Mar 17Eurofins Scientific SE (EPA:ERF) Has Got What It Takes To Be An Attractive Dividend Stock
Mar 03Eurofins Scientific SE Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Mar 03Are Institutions Heavily Invested In Eurofins Scientific SE's (EPA:ERF) Shares?
Feb 15
Is Eurofins Scientific's (EPA:ERF) 117% Share Price Increase Well Justified?
Dec 28How Does Eurofins Scientific's (EPA:ERF) CEO Pay Compare With Company Performance?
Dec 14Eurofins Scientific (EPA:ERF) Is Growing Earnings But Are They A Good Guide?
Nov 30Rendement voor aandeelhouders
| ERF | FR Life Sciences | FR Markt | |
|---|---|---|---|
| 7D | 6.3% | 2.0% | 0.9% |
| 1Y | 9.2% | 3.4% | 5.0% |
Rendement versus industrie: ERF exceeded the French Life Sciences industry which returned 3.5% over the past year.
Rendement versus markt: ERF exceeded the French Market which returned 4.9% over the past year.
Prijsvolatiliteit
| ERF volatility | |
|---|---|
| ERF Average Weekly Movement | 4.0% |
| Life Sciences Industry Average Movement | 6.3% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in FR Market | 9.6% |
| 10% least volatile stocks in FR Market | 2.2% |
Stabiele aandelenkoers: ERF has not had significant price volatility in the past 3 months.
Volatiliteit in de loop van de tijd: ERF's weekly volatility (4%) has been stable over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1987 | 61,798 | Gilles Martin | www.eurofins.com |
Eurofins Scientific SE biedt, samen met haar dochterondernemingen, wereldwijd diverse analytische test- en laboratoriumdiensten aan. Het bedrijf biedt een portfolio van verschillende analytische methoden en testen om de veiligheid, identiteit, samenstelling, authenticiteit, oorsprong, traceerbaarheid en zuiverheid van verschillende producten te evalueren. Het bedrijf levert diensten op het gebied van agrowetenschap, waaronder biologische beoordeling, consumenten-, menselijke en milieuveiligheid, productchemie, consultancy op het gebied van regelgeving en zaaddiensten; agrotests; garantie, zoals productinspectie, auditing, certificering, training en advies op het gebied van voeding, consumentenproducten, gezondheidszorg en cosmetica, en voedingssupplementen; biofarma en klinische diagnostiek.
Eurofins Scientific SE Samenvatting
| ERF fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | €10.87b |
| Inkomsten(TTM) | €325.90m |
| Inkomsten(TTM) | €6.72b |
33.3x
Koers/Winstverhouding1.6x
P/S-verhoudingIs ERF overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| ERF resultatenrekening (TTM) | |
|---|---|
| Inkomsten | €6.72b |
| Kosten van inkomsten | €5.23b |
| Brutowinst | €1.49b |
| Overige uitgaven | €1.17b |
| Inkomsten | €325.90m |
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 1.70 |
| Brutomarge | 22.19% |
| Nettowinstmarge | 4.85% |
| Schuld/Eigen Vermogen Verhouding | 55.3% |
Hoe presteerde ERF op de lange termijn?
Bekijk historische prestaties en vergelijking